Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

JR Perry, N Laperriere, CJ O'Callaghan, AA Brandes, J Menten, C Phillips, M Fay, R Nishikawa, JG Cairncross, W Roa, D Osoba, JP Rossiter, A Sahgal, H Hirte, F Laigle-Donadey, E Franceschi, O Chinot, V Golfinopoulos, L Fariselli, A WickL Feuvret, M Back, M Tills, C Winch, BG Baumert, W Wick, K Ding, WP Mason, for the Trial Investigators, Michele Reni

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy is added to standard radiotherapy (60 Gy over a period of 6 weeks). In elderly patients, more convenient shorter courses of radiotherapy are commonly used, but the benefit of adding temozolomide to a shorter course of radiotherapy is unknown. METHODS: We conducted a trial involving patients 65 years of age or older with newly diagnosed glioblastoma. Patients were randomly assigned to receive either radiotherapy alone (40 Gy in 15 fractions) or radiotherapy with concomitant and adjuvant temozolomide. RESULTS: A total of 562 patients underwent randomization, 281 to each group. The median age was 73 years (range, 65 to 90). The median overall survival was longer with radiotherapy plus temozolomide than with radiotherapy alone (9.3 months vs. 7.6 months; hazard ratio for death, 0.67; 95% confidence interval [CI], 0.56 to 0.80; P
Original languageEnglish
Pages (from-to)1027-1037
Number of pages11
JournalNew England Journal of Medicine
Volume376
Issue number11
DOIs
Publication statusPublished - 2017

Fingerprint

temozolomide
Glioblastoma
Radiotherapy
Radiation
Survival
Random Allocation

Cite this

Perry, JR., Laperriere, N., O'Callaghan, CJ., Brandes, AA., Menten, J., Phillips, C., ... Reni, M. (2017). Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. New England Journal of Medicine, 376(11), 1027-1037. https://doi.org/10.1056/NEJMoa1611977

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. / Perry, JR; Laperriere, N; O'Callaghan, CJ; Brandes, AA; Menten, J; Phillips, C; Fay, M; Nishikawa, R; Cairncross, JG; Roa, W; Osoba, D; Rossiter, JP; Sahgal, A; Hirte, H; Laigle-Donadey, F; Franceschi, E; Chinot, O; Golfinopoulos, V; Fariselli, L; Wick, A; Feuvret, L; Back, M; Tills, M; Winch, C; Baumert, BG; Wick, W; Ding, K; Mason, WP; Investigators, for the Trial; Reni, Michele.

In: New England Journal of Medicine, Vol. 376, No. 11, 2017, p. 1027-1037.

Research output: Contribution to journalArticle

Perry, JR, Laperriere, N, O'Callaghan, CJ, Brandes, AA, Menten, J, Phillips, C, Fay, M, Nishikawa, R, Cairncross, JG, Roa, W, Osoba, D, Rossiter, JP, Sahgal, A, Hirte, H, Laigle-Donadey, F, Franceschi, E, Chinot, O, Golfinopoulos, V, Fariselli, L, Wick, A, Feuvret, L, Back, M, Tills, M, Winch, C, Baumert, BG, Wick, W, Ding, K, Mason, WP, Investigators, FTT & Reni, M 2017, 'Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma', New England Journal of Medicine, vol. 376, no. 11, pp. 1027-1037. https://doi.org/10.1056/NEJMoa1611977
Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C et al. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. New England Journal of Medicine. 2017;376(11):1027-1037. https://doi.org/10.1056/NEJMoa1611977
Perry, JR ; Laperriere, N ; O'Callaghan, CJ ; Brandes, AA ; Menten, J ; Phillips, C ; Fay, M ; Nishikawa, R ; Cairncross, JG ; Roa, W ; Osoba, D ; Rossiter, JP ; Sahgal, A ; Hirte, H ; Laigle-Donadey, F ; Franceschi, E ; Chinot, O ; Golfinopoulos, V ; Fariselli, L ; Wick, A ; Feuvret, L ; Back, M ; Tills, M ; Winch, C ; Baumert, BG ; Wick, W ; Ding, K ; Mason, WP ; Investigators, for the Trial ; Reni, Michele. / Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. In: New England Journal of Medicine. 2017 ; Vol. 376, No. 11. pp. 1027-1037.
@article{e7c544eec27640e0b7b268300ba983eb,
title = "Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma",
abstract = "BACKGROUND: Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy is added to standard radiotherapy (60 Gy over a period of 6 weeks). In elderly patients, more convenient shorter courses of radiotherapy are commonly used, but the benefit of adding temozolomide to a shorter course of radiotherapy is unknown. METHODS: We conducted a trial involving patients 65 years of age or older with newly diagnosed glioblastoma. Patients were randomly assigned to receive either radiotherapy alone (40 Gy in 15 fractions) or radiotherapy with concomitant and adjuvant temozolomide. RESULTS: A total of 562 patients underwent randomization, 281 to each group. The median age was 73 years (range, 65 to 90). The median overall survival was longer with radiotherapy plus temozolomide than with radiotherapy alone (9.3 months vs. 7.6 months; hazard ratio for death, 0.67; 95{\%} confidence interval [CI], 0.56 to 0.80; P",
author = "JR Perry and N Laperriere and CJ O'Callaghan and AA Brandes and J Menten and C Phillips and M Fay and R Nishikawa and JG Cairncross and W Roa and D Osoba and JP Rossiter and A Sahgal and H Hirte and F Laigle-Donadey and E Franceschi and O Chinot and V Golfinopoulos and L Fariselli and A Wick and L Feuvret and M Back and M Tills and C Winch and BG Baumert and W Wick and K Ding and WP Mason and Investigators, {for the Trial} and Michele Reni",
note = "Reni, M con affiliazione",
year = "2017",
doi = "10.1056/NEJMoa1611977",
language = "English",
volume = "376",
pages = "1027--1037",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "11",

}

TY - JOUR

T1 - Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

AU - Perry, JR

AU - Laperriere, N

AU - O'Callaghan, CJ

AU - Brandes, AA

AU - Menten, J

AU - Phillips, C

AU - Fay, M

AU - Nishikawa, R

AU - Cairncross, JG

AU - Roa, W

AU - Osoba, D

AU - Rossiter, JP

AU - Sahgal, A

AU - Hirte, H

AU - Laigle-Donadey, F

AU - Franceschi, E

AU - Chinot, O

AU - Golfinopoulos, V

AU - Fariselli, L

AU - Wick, A

AU - Feuvret, L

AU - Back, M

AU - Tills, M

AU - Winch, C

AU - Baumert, BG

AU - Wick, W

AU - Ding, K

AU - Mason, WP

AU - Investigators, for the Trial

AU - Reni, Michele

N1 - Reni, M con affiliazione

PY - 2017

Y1 - 2017

N2 - BACKGROUND: Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy is added to standard radiotherapy (60 Gy over a period of 6 weeks). In elderly patients, more convenient shorter courses of radiotherapy are commonly used, but the benefit of adding temozolomide to a shorter course of radiotherapy is unknown. METHODS: We conducted a trial involving patients 65 years of age or older with newly diagnosed glioblastoma. Patients were randomly assigned to receive either radiotherapy alone (40 Gy in 15 fractions) or radiotherapy with concomitant and adjuvant temozolomide. RESULTS: A total of 562 patients underwent randomization, 281 to each group. The median age was 73 years (range, 65 to 90). The median overall survival was longer with radiotherapy plus temozolomide than with radiotherapy alone (9.3 months vs. 7.6 months; hazard ratio for death, 0.67; 95% confidence interval [CI], 0.56 to 0.80; P

AB - BACKGROUND: Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy is added to standard radiotherapy (60 Gy over a period of 6 weeks). In elderly patients, more convenient shorter courses of radiotherapy are commonly used, but the benefit of adding temozolomide to a shorter course of radiotherapy is unknown. METHODS: We conducted a trial involving patients 65 years of age or older with newly diagnosed glioblastoma. Patients were randomly assigned to receive either radiotherapy alone (40 Gy in 15 fractions) or radiotherapy with concomitant and adjuvant temozolomide. RESULTS: A total of 562 patients underwent randomization, 281 to each group. The median age was 73 years (range, 65 to 90). The median overall survival was longer with radiotherapy plus temozolomide than with radiotherapy alone (9.3 months vs. 7.6 months; hazard ratio for death, 0.67; 95% confidence interval [CI], 0.56 to 0.80; P

U2 - 10.1056/NEJMoa1611977

DO - 10.1056/NEJMoa1611977

M3 - Article

VL - 376

SP - 1027

EP - 1037

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 11

ER -